TickerTalks
Browse all tickers →
TickerTalks›$SRPT
SRSRPT

Sarepta Therapeutics, Inc.

$SRPT·$1.8B·Biotechnology·Healthcare
$22.50-2.1%YTD-25.2%1Y+21.9%
Mentions · last 7 days
2026-08-29: 7 posts2026-08-30: 3 posts2026-08-31: 32 posts2026-09-01: 18 posts2026-09-02: 48 posts2026-09-03: 27 posts2026-09-04: 5 posts141+25%
Price updated 10h ago·X counts updated 8h ago
SRSRPT
$SRPTSarepta Therapeutics, Inc.
$22.50-2.13%141 posts+25%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $SRPT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-09-04

The move is getting stronger, with heavier trading behind it.

Sarepta is running hard on SIRNA-pipeline momentum — a 16-to-1 call/put ratio, +50% call gains, and the crowd calling for $50 and $75.

Sarepta Therapeutics is a rare-disease biotech best known for Elevidys (DMD gene therapy) and a broader neuromuscular pipeline. The equity has been on a violent run after being written off, and options flow suggests institutional accumulation.

  • The options tape is exceptional: flow ratio at 10,694 calls to 650 puts (16-to-1 skew) with +50% call gains and +43% month-over-month equity performance — that's the kind of options flow that indicates smart-money accumulation rather than retail speculation, and it's a signal that typically precedes an earnings catalyst or a strategic development.
  • The revenue picture is choppy but improving: Q1 revenue was $731M, up slightly YoY, with prior quarters at -33%, -15%, +68% — very lumpy, meaning consensus and reality diverge often; but the run-rate is stabilizing, and gross margin at 84% shows the underlying commercial economics still work when volume shows up.
  • The SIRNA pipeline is the specific bull thesis: SIRNA-based programs remain the identified upside driver in the pitch to $75 — for a company with a $1.77B market cap trading at ~1x sales, any dated readout or partnership on the SIRNA pipeline is a specific catalyst that could reprice the equity significantly.

November 4 Q3 earnings and any SIRNA program interim data are the near-term catalysts. A print with revenue reacceleration and any partnership disclosure validates the $50 crowd target; a lumpy quarter without pipeline news resets the call-heavy positioning. Watch Elevidys script trajectory and SIRNA readout timing.

Agrees with X sentimentI agree with the bull framing — the 10,694 calls to 650 puts flow ratio, +50% call gains, and +43% MoM performance are the load-bearing setup, and the SIRNA-pipeline path to $75 is a legitimate targeted upside; the caveat is that the underlying revenue trajectory is still choppy.

What to watch: November 4 Q3 earnings and any SIRNA interim data. A print with revenue reacceleration and a partnership disclosure validates the $50 target; a lumpy quarter without pipeline news resets the call-heavy positioning; watch Elevidys script trajectory.

On the calendar: 2026-11-04 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment22 posts analyzed · as of 2026-09-04

$SRPT (Sarepta) chatter is loudly bullish. SRPT +50% in the last month with bulls targeting $35 → $50 → $75+ (siRNA pipeline). Enhanced sirolimus study for AMB started 8/31/26 (1 year). Bulls note Morgan Stanley conference 9/14 could be 'Dr. Severino coming out party.' 10,694 calls vs. 650 puts today. Year-end clinical data catalyst. Stock rose ~12.9% on 8/27 to $21.98. Overall bullish setup.

Read the AI verdict + X sentiment for $SRPT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Commercial-stage biotech with approved exon-skipping drugs for Duchenne muscular dystrophy (EXONDYS 51, VYONDYS 53) and a gene therapy pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SRPT.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $SRPT

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
30.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-1.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-1.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
4.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
62.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.05$0.22-123.0%
Q1 2026May 6, 2026$3.16$0.98+223.8%
Q4 2025Feb 25, 2026$-3.58$-1.03-247.6%
Q3 2025Nov 3, 2025$-1.80$-0.73-147.6%
Next earningsWed, Nov 4·consensus EPS $0.17

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$730.8M-1.9%83.7%49.0%$3.15$-205.8M
Q4 FY25$442.9M-32.7%10.0%-92.9%$-2.74$125.4M
Q3 FY25$399.4M-14.5%62.2%-25.9%$-1.80$-42.8M
Q2 FY25$611.1M+68.4%75.0%18.9%$2.01$229.4M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.8B$1.7B – $2.1B$3.67$2.66 – $4.8516
FY27$1.4B$1.3B – $1.6B$0.86$0.51 – $1.1915
FY28$1.4B$1.4B – $1.4B$0.69-$3.47 – $2.2514
FY29$1.3B$1.1B – $1.5B$0.26$0.21 – $0.319
FY30$1.3B$1.1B – $1.5B$0.24$0.19 – $0.2813

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.73%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+23.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+17.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 94.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.205-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMar 12Stephen MayoDirector7.2K sh$123K
+ 17 other (9 awards · 8 inkinds) in window

See when $SRPT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 293
AI summary

SEVERINO MICHAEL filed a Form 3 (initial statement of beneficial ownership) for Sarepta Therapeutics, Inc. (SRPT). Filer's relationship to issuer: Director, Chief Executive Officer, 10%+ Owner. Form 3 must be filed within 10 days of becoming a new 10%+ owner or executive/director. This is an administrative ownership disclosure — no open-market transaction has occurred.

8-KOfficer or director changeJul 278-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Sarepta Therapeutics, Inc (SRPT) disclosed an executive/director departure (Item 5.02, filed 2026-07-27). ure of Directors departed from Directors or Certain Officers. Compensation and transition details are in the exhibits. Leadership changes can signal strategic shifts; investors should assess continuity and the appointee's background.

8-KOfficer or director changeJun 48-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Sarepta Therapeutics held its 2026 Annual Meeting on June 4, 2026 (77.97% quorum). Shareholders approved the new 2026 Equity Incentive Plan (6,286,841 shares, replacing the 2018 plan) and 2026 Employee Stock Purchase Plan (1,500,000 shares, replacing the 2013 plan). Specific vote tallies are referenced but not reproduced in the excerpt. Both equity plans represent net new share authorization of approximately 7.8 million shares; routine plan refresh that maintains Sarepta's ability to grant competitive equity compensation.

+ 18 other (7 13Gs · 2 13Fs · 2 earnings 8-Ks · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?zacks.com·19h agoCanada Pension Plan Investment Board Buys Shares of 70,800 Sarepta Therapeutics, Inc. $SRPTdefenseworld.net·4d agoSarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conferencebusinesswire.com·5d agoSarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPTbusinesswire.com·12d agoBank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPTdefenseworld.net·23d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$MRNA$ALT$NWBO$SLS$RARE$IBRX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport